← Back to The Absolute Effect
Testicular Germ-Cell Tumours · Medical Oncology · Relapsed GCT · second-line salvage

VeIP as initial salvage chemotherapy

After relapse following cisplatin/etoposide-based chemotherapy, what outcomes were reported with VeIP salvage chemotherapy?

Mixed germ-cell tumour cohort; not seminoma-specific

Population
135

Study population as reported in the cited publication; cohort sizes and denominators are stated where available.

Evidence type
Mixed GCT

Not all evidence is randomized, comparative, or seminoma-specific.

Reported outcomes

In 135 patients, 67 (49.6%) achieved disease-free status after chemotherapy with or without surgery. Thirty-two (23.7%) were continuously disease-free at long-term follow-up.

Disease-free after chemotherapy ± surgery67/135
Continuously disease-free32/135

Bars visualize source-reported percentages; where the denominator is shown, it is the observed count/denominator rather than a comparative treatment effect. NNT is not calculated for single-arm cohorts or non-randomized comparisons.

Interpretation and limitations

Cisplatin-refractory patients progressing within 3 weeks were excluded. Results combine histologies and include the effect of surgery; do not interpret as a seminoma-only response rate.

Guideline context: ESMO–EURACAN recommends standard-dose VIP/PEI, TIP or VeIP as conventional first salvage options after relapse following cisplatin-based chemotherapy. NCCN Testicular Cancer Guidelines Insights (Version 2.2025) is a contemporary US guideline source. The study summarized here is not necessarily seminoma-specific; histology scope is stated explicitly below.

Guidelines: ESMO–EURACAN 2022 · NCCN Insights v2.2025

Primary study source

Loehrer PJ Sr, Gonin R, Nichols CR, Weathers T, Einhorn LH. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol. 1998;16:2500–2504.

Original study / PubMed / registry ↗

Evidence review date: 18 October 2026. Confirm regimen choice and dose schedules against current guideline text and an expert germ-cell tumour multidisciplinary team.